Immunohistochemical Analysis of MUC5B Apomucin Expression in Breast Cancer and Non-malignant Breast Tissues

• Published in: The journal of histochemistry and cytochemistry 2006-03, Vol.54 (3), p.289-299
• Main Authors: Sonora, Cecilia, Mazal, Daniel, Berois, Nora, Buisine, Marie-Pierre, Ubillos, Luis, Varangot, Mario, Barrios, Enrique, Carzoglio, Julio, Aubert, Jean-Pierre, Osinaga, Eduardo
• Format: Article
• Language: English
• Subjects: Adenocarcinoma, Mucinous - metabolism; Adult; Aged; Aged, 80 and over; Apoproteins - biosynthesis; Blotting, Western; Bone Marrow - metabolism; Breast - metabolism; Breast Diseases - metabolism; Breast Neoplasms - metabolism; Carcinoma, Ductal, Breast - metabolism; Carcinoma, Lobular - metabolism; Carcinoma, Papillary - metabolism; Cell Line, Tumor; Female; Humans; Immunohistochemistry; In Situ Hybridization; Mammary Glands, Human - metabolism; Middle Aged; Mucin-5B; Mucins - biosynthesis; Mucins - genetics; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation
• ISSN: 0022-1554; 1551-5044
• DOI: 10.1369/jhc.5A6763.2005

A deregulation of several MUC genes (MUC1, MUC2, MUC3, MUC5AC, and MUC6) was previously demonstrated in breast carcinomas. Considering that recently we found the “non-mammary” MUC5B mRNA in primary breast tumors (Berois et al. 2003), we undertook the present study to evaluate the expression profile of MUC5B protein product in breast tissues, using LUM5B-2 antisera raised against sequences within the non-glycosylated regions of this apomucin. Expression of MUC5B by breast cancer cells was confirmed by immunocytochemistry, in situ hybridization, and Western blot on MCF-7 cancer cells. Using an immunohistochemical procedure, MUC5B apomucin was detected in 34/42 (81%) primary breast tumors, in 13/14 (92.8%) samples of non-malignant breast diseases, in 8/19 (42.1%) samples of normal-appearing breast epithelia adjacent to cancer, and in 0/5 normal control breast samples. The staining pattern of MUC5B was very different when comparing breast cancer cells (cytoplasmic) and non-malignant breast cells (predominantly apical and in the secretory material). We analyzed MUC5B mRNA expression using RT-PCR in bone marrow aspirates from 22/42 patients with breast cancer to compare with MUC5B protein expression in the primary tumors. Good correlation was observed because the six MUC5B-positive bone marrow samples also displayed MUC5B expression in the tumor. Our results show, for the first time at the protein level, that MUC5B apomucin is upregulated in breast cancer. Its characterization could provide new insights about the glycobiology of breast cancer cells.